

Global Small Molecule Multi-target Angiogenesis Inhibitor Market Growth 2026-2032

<https://marketpublishers.com/r/G59FAA353A5AEN.html>

Date: February 2026

Pages: 122

Price: US\$ 3,660.00 (Single User License)

ID: G59FAA353A5AEN

Abstracts

The global Small Molecule Multi-target Angiogenesis Inhibitor market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

A Small Molecule Multi-target Angiogenesis Inhibitor (SMMTAI) represents a class of therapeutic compounds designed to inhibit angiogenesis by targeting multiple molecular pathways involved in blood vessel formation. Unlike single-target inhibitors, SMMTAIs typically interact with several key molecules. By blocking these diverse pathways simultaneously, SMMTAIs aim to comprehensively disrupt the intricate process of angiogenesis, which is critical for tumor growth and progression of diseases like age-related macular degeneration.

United States market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Small Molecule Multi-target Angiogenesis Inhibitor players cover Bayer, Teva, TWi Pharmaceuticals, Pfizer, Novartis, etc. In terms of revenue, the global two

largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the “Small Molecule Multi-target Angiogenesis Inhibitor Industry Forecast” looks at past sales and reviews total world Small Molecule Multi-target Angiogenesis Inhibitor sales in 2025, providing a comprehensive analysis by region and market sector of projected Small Molecule Multi-target Angiogenesis Inhibitor sales for 2026 through 2032. With Small Molecule Multi-target Angiogenesis Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Small Molecule Multi-target Angiogenesis Inhibitor industry.

This Insight Report provides a comprehensive analysis of the global Small Molecule Multi-target Angiogenesis Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Small Molecule Multi-target Angiogenesis Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Small Molecule Multi-target Angiogenesis Inhibitor market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Small Molecule Multi-target Angiogenesis Inhibitor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Small Molecule Multi-target Angiogenesis Inhibitor.

This report presents a comprehensive overview, market shares, and growth opportunities of Small Molecule Multi-target Angiogenesis Inhibitor market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Sorafenib

Sunitinib

Apatinib

Anlotinib

Lenvatinib

Vandetanib

Cabozantinib

Pazopanib

Axitinib

Other

Segmentation by Application:

Cancer Therapy

Ophthalmic Diseases

Inflammatory and Autoimmune Diseases

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Bayer

Teva

TWi Pharmaceuticals

Pfizer

Novartis

AstraZeneca.

Sanofi

Exelixis

Boehringer Ingelheim

Eisai

Janssen Biotech

Jiangsu Hengrui Pharmaceuticals

Chia Tai Tianqing

Key Questions Addressed in this Report

What is the 10-year outlook for the global Small Molecule Multi-target Angiogenesis Inhibitor market?

What factors are driving Small Molecule Multi-target Angiogenesis Inhibitor market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Small Molecule Multi-target Angiogenesis Inhibitor market opportunities vary by end market size?

How does Small Molecule Multi-target Angiogenesis Inhibitor break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Small Molecule Multi-target Angiogenesis Inhibitor by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Small Molecule Multi-target Angiogenesis Inhibitor by Country/Region, 2021, 2025 & 2032

2.2 Small Molecule Multi-target Angiogenesis Inhibitor Segment by Type

- 2.2.1 Sorafenib
- 2.2.2 Sunitinib
- 2.2.3 Apatinib
- 2.2.4 Anlotinib
- 2.2.5 Lenvatinib
- 2.2.6 Vandetanib
- 2.2.7 Cabozantinib
- 2.2.8 Pazopanib
- 2.2.9 Axitinib
- 2.2.10 Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type
 - 2.2.10.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026)
 - 2.2.10.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue and Market Share by Type (2021-2026)
 - 2.2.10.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Price by Type (2021-2026)

2.3 Small Molecule Multi-target Angiogenesis Inhibitor Segment by Application

2.3.1 Cancer Therapy

2.3.2 Ophthalmic Diseases

2.3.3 Inflammatory and Autoimmune Diseases

2.3.4 Other

2.3.5 Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application

2.3.5.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Market Share by Application (2021-2026)

2.3.5.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue and Market Share by Application (2021-2026)

2.3.5.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Breakdown Data by Company

3.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Annual Sales by Company (2021-2026)

3.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Company (2021-2026)

3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Annual Revenue by Company (2021-2026)

3.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Company (2021-2026)

3.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Company (2021-2026)

3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Price by Company

3.4 Key Manufacturers Small Molecule Multi-target Angiogenesis Inhibitor Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Small Molecule Multi-target Angiogenesis Inhibitor Product Location Distribution

3.4.2 Players Small Molecule Multi-target Angiogenesis Inhibitor Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR BY GEOGRAPHIC REGION

4.1 World Historic Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Geographic Region (2021-2026)

4.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country/Region (2021-2026)

4.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Annual Sales by Country/Region (2021-2026)

4.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Annual Revenue by Country/Region (2021-2026)

4.3 Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth

4.4 APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth

4.5 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth

4.6 Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth

5 AMERICAS

5.1 Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country

5.1.1 Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)

5.1.2 Americas Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021-2026)

5.2 Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026)

5.3 Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region

6.1.1 APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2026)

6.1.2 APAC Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2021-2026)

6.2 APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026)

6.3 APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor by Country

7.1.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)

7.1.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021-2026)

7.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026)

7.3 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor by Country

8.1.1 Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)

8.1.2 Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021-2026)

8.2 Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026)

8.3 Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Small Molecule Multi-target Angiogenesis Inhibitor

10.3 Manufacturing Process Analysis of Small Molecule Multi-target Angiogenesis Inhibitor

10.4 Industry Chain Structure of Small Molecule Multi-target Angiogenesis Inhibitor

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Small Molecule Multi-target Angiogenesis Inhibitor Distributors

11.3 Small Molecule Multi-target Angiogenesis Inhibitor Customer

12 WORLD FORECAST REVIEW FOR SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR BY GEOGRAPHIC REGION

12.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by

Region

12.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Forecast by Region (2027-2032)

12.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Small Molecule Multi-target Angiogenesis Inhibitor Forecast by Type (2027-2032)

12.7 Global Small Molecule Multi-target Angiogenesis Inhibitor Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Bayer

13.1.1 Bayer Company Information

13.1.2 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

13.1.3 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Bayer Main Business Overview

13.1.5 Bayer Latest Developments

13.2 Teva

13.2.1 Teva Company Information

13.2.2 Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

13.2.3 Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Teva Main Business Overview

13.2.5 Teva Latest Developments

13.3 TWi Pharmaceuticals

13.3.1 TWi Pharmaceuticals Company Information

13.3.2 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

13.3.3 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 TWi Pharmaceuticals Main Business Overview

- 13.3.5 TWi Pharmaceuticals Latest Developments
- 13.4 Pfizer
 - 13.4.1 Pfizer Company Information
 - 13.4.2 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.4.3 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Pfizer Main Business Overview
 - 13.4.5 Pfizer Latest Developments
- 13.5 Novartis
 - 13.5.1 Novartis Company Information
 - 13.5.2 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.5.3 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Novartis Main Business Overview
 - 13.5.5 Novartis Latest Developments
- 13.6 AstraZeneca.
 - 13.6.1 AstraZeneca. Company Information
 - 13.6.2 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.6.3 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 AstraZeneca. Main Business Overview
 - 13.6.5 AstraZeneca. Latest Developments
- 13.7 Sanofi
 - 13.7.1 Sanofi Company Information
 - 13.7.2 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.7.3 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 Sanofi Main Business Overview
 - 13.7.5 Sanofi Latest Developments
- 13.8 Exelixis
 - 13.8.1 Exelixis Company Information
 - 13.8.2 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.8.3 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.8.4 Exelixis Main Business Overview
- 13.8.5 Exelixis Latest Developments
- 13.9 Boehringer Ingelheim
 - 13.9.1 Boehringer Ingelheim Company Information
 - 13.9.2 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.9.3 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 Boehringer Ingelheim Main Business Overview
 - 13.9.5 Boehringer Ingelheim Latest Developments
- 13.10 Eisai
 - 13.10.1 Eisai Company Information
 - 13.10.2 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.10.3 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.10.4 Eisai Main Business Overview
 - 13.10.5 Eisai Latest Developments
- 13.11 Janssen Biotech
 - 13.11.1 Janssen Biotech Company Information
 - 13.11.2 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.11.3 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.11.4 Janssen Biotech Main Business Overview
 - 13.11.5 Janssen Biotech Latest Developments
- 13.12 Jiangsu Hengrui Pharmaceuticals
 - 13.12.1 Jiangsu Hengrui Pharmaceuticals Company Information
 - 13.12.2 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.12.3 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.12.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
 - 13.12.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
- 13.13 Chia Tai Tianqing
 - 13.13.1 Chia Tai Tianqing Company Information
 - 13.13.2 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications
 - 13.13.3 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales,

Revenue, Price and Gross Margin (2021-2026)

13.13.4 Chia Tai Tianqing Main Business Overview

13.13.5 Chia Tai Tianqing Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Small Molecule Multi-target Angiogenesis Inhibitor Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Small Molecule Multi-target Angiogenesis Inhibitor Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Sorafenib

Table 4. Major Players of Sunitinib

Table 5. Major Players of Apatinib

Table 6. Major Players of Anlotinib

Table 7. Major Players of Lenvatinib

Table 8. Major Players of Vandetanib

Table 9. Major Players of Cabozantinib

Table 10. Major Players of Pazopanib

Table 11. Major Players of Axitinib

Table 12. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units)

Table 13. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026)

Table 14. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021-2026) & (\$ million)

Table 15. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2026)

Table 16. Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Price by Type (2021-2026) & (US\$/Unit)

Table 17. Global Small Molecule Multi-target Angiogenesis Inhibitor Sale by Application (2021-2026) & (K Units)

Table 18. Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Market Share by Application (2021-2026)

Table 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021-2026) & (\$ million)

Table 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2026)

Table 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Price by Application (2021-2026) & (US\$/Unit)

Table 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Company (2021-2026) & (K Units)

Table 23. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Company (2021-2026)

Table 24. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Company (2021-2026) & (\$ millions)

Table 25. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Company (2021-2026)

Table 26. Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Price by Company (2021-2026) & (US\$/Unit)

Table 27. Key Manufacturers Small Molecule Multi-target Angiogenesis Inhibitor Producing Area Distribution and Sales Area

Table 28. Players Small Molecule Multi-target Angiogenesis Inhibitor Products Offered

Table 29. Small Molecule Multi-target Angiogenesis Inhibitor Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 30. New Products and Potential Entrants

Table 31. Market M&A Activity & Strategy

Table 32. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Geographic Region (2021-2026) & (K Units)

Table 33. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share Geographic Region (2021-2026)

Table 34. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 35. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Geographic Region (2021-2026)

Table 36. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country/Region (2021-2026) & (K Units)

Table 37. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country/Region (2021-2026)

Table 38. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country/Region (2021-2026) & (\$ millions)

Table 39. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country/Region (2021-2026)

Table 40. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units)

Table 41. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2026)

Table 42. Americas Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021-2026) & (\$ millions)

Table 43. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units)

- Table 44. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units)
- Table 45. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2026) & (K Units)
- Table 46. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021-2026)
- Table 47. APAC Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2021-2026) & (\$ millions)
- Table 48. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units)
- Table 49. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units)
- Table 50. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units)
- Table 51. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021-2026) & (\$ millions)
- Table 52. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units)
- Table 53. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units)
- Table 54. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units)
- Table 55. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021-2026)
- Table 56. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units)
- Table 57. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units)
- Table 58. Key Market Drivers & Growth Opportunities of Small Molecule Multi-target Angiogenesis Inhibitor
- Table 59. Key Market Challenges & Risks of Small Molecule Multi-target Angiogenesis Inhibitor
- Table 60. Key Industry Trends of Small Molecule Multi-target Angiogenesis Inhibitor
- Table 61. Small Molecule Multi-target Angiogenesis Inhibitor Raw Material
- Table 62. Key Suppliers of Raw Materials
- Table 63. Small Molecule Multi-target Angiogenesis Inhibitor Distributors List
- Table 64. Small Molecule Multi-target Angiogenesis Inhibitor Customer List
- Table 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Region (2027-2032) & (K Units)

Table 66. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 67. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032) & (K Units)

Table 68. Americas Small Molecule Multi-target Angiogenesis Inhibitor Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 69. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Region (2027-2032) & (K Units)

Table 70. APAC Small Molecule Multi-target Angiogenesis Inhibitor Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 71. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032) & (K Units)

Table 72. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 73. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032) & (K Units)

Table 74. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 75. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Type (2027-2032) & (K Units)

Table 76. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 77. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Application (2027-2032) & (K Units)

Table 78. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 79. Bayer Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 80. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 81. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 82. Bayer Main Business

Table 83. Bayer Latest Developments

Table 84. Teva Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 85. Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 86. Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 87. Teva Main Business

Table 88. Teva Latest Developments

Table 89. TWi Pharmaceuticals Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 90. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 91. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 92. TWi Pharmaceuticals Main Business

Table 93. TWi Pharmaceuticals Latest Developments

Table 94. Pfizer Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 95. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 96. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 97. Pfizer Main Business

Table 98. Pfizer Latest Developments

Table 99. Novartis Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 100. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 101. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 102. Novartis Main Business

Table 103. Novartis Latest Developments

Table 104. AstraZeneca. Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 105. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 106. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 107. AstraZeneca. Main Business

Table 108. AstraZeneca. Latest Developments

Table 109. Sanofi Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 110. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 111. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 112. Sanofi Main Business

Table 113. Sanofi Latest Developments

Table 114. Exelixis Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 115. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 116. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 117. Exelixis Main Business

Table 118. Exelixis Latest Developments

Table 119. Boehringer Ingelheim Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 120. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 121. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 122. Boehringer Ingelheim Main Business

Table 123. Boehringer Ingelheim Latest Developments

Table 124. Eisai Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 125. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 126. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 127. Eisai Main Business

Table 128. Eisai Latest Developments

Table 129. Janssen Biotech Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 130. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 131. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 132. Janssen Biotech Main Business

Table 133. Janssen Biotech Latest Developments

Table 134. Jiangsu Hengrui Pharmaceuticals Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 135. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis

Inhibitor Product Portfolios and Specifications

Table 136. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 137. Jiangsu Hengrui Pharmaceuticals Main Business

Table 138. Jiangsu Hengrui Pharmaceuticals Latest Developments

Table 139. Chia Tai Tianqing Basic Information, Small Molecule Multi-target Angiogenesis Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 140. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolios and Specifications

Table 141. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 142. Chia Tai Tianqing Main Business

Table 143. Chia Tai Tianqing Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Small Molecule Multi-target Angiogenesis Inhibitor
- Figure 2. Small Molecule Multi-target Angiogenesis Inhibitor Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Small Molecule Multi-target Angiogenesis Inhibitor Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country/Region (2025)
- Figure 10. Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Sorafenib
- Figure 12. Product Picture of Sunitinib
- Figure 13. Product Picture of Apatinib
- Figure 14. Product Picture of Anlotinib
- Figure 15. Product Picture of Lenvatinib
- Figure 16. Product Picture of Vandetanib
- Figure 17. Product Picture of Cabozantinib
- Figure 18. Product Picture of Pazopanib
- Figure 19. Product Picture of Axitinib
- Figure 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type in 2026
- Figure 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2026)
- Figure 22. Small Molecule Multi-target Angiogenesis Inhibitor Consumed in Cancer Therapy
- Figure 23. Global Small Molecule Multi-target Angiogenesis Inhibitor Market: Cancer Therapy (2021-2026) & (K Units)
- Figure 24. Small Molecule Multi-target Angiogenesis Inhibitor Consumed in Ophthalmic Diseases
- Figure 25. Global Small Molecule Multi-target Angiogenesis Inhibitor Market:

Ophthalmic Diseases (2021-2026) & (K Units)

Figure 26. Small Molecule Multi-target Angiogenesis Inhibitor Consumed in Inflammatory and Autoimmune Diseases

Figure 27. Global Small Molecule Multi-target Angiogenesis Inhibitor Market: Inflammatory and Autoimmune Diseases (2021-2026) & (K Units)

Figure 28. Small Molecule Multi-target Angiogenesis Inhibitor Consumed in Other

Figure 29. Global Small Molecule Multi-target Angiogenesis Inhibitor Market: Other (2021-2026) & (K Units)

Figure 30. Global Small Molecule Multi-target Angiogenesis Inhibitor Sale Market Share by Application (2025)

Figure 31. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application in 2026

Figure 32. Small Molecule Multi-target Angiogenesis Inhibitor Sales by Company in 2026 (K Units)

Figure 33. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Company in 2026

Figure 34. Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Company in 2026 (\$ millions)

Figure 35. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Company in 2026

Figure 36. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Geographic Region (2021-2026)

Figure 37. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Geographic Region in 2026

Figure 38. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales 2021-2026 (K Units)

Figure 39. Americas Small Molecule Multi-target Angiogenesis Inhibitor Revenue 2021-2026 (\$ millions)

Figure 40. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales 2021-2026 (K Units)

Figure 41. APAC Small Molecule Multi-target Angiogenesis Inhibitor Revenue 2021-2026 (\$ millions)

Figure 42. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales 2021-2026 (K Units)

Figure 43. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue 2021-2026 (\$ millions)

Figure 44. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales 2021-2026 (K Units)

Figure 45. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor

Revenue 2021-2026 (\$ millions)

Figure 46. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country in 2026

Figure 47. Americas Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021-2026)

Figure 48. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026)

Figure 49. Americas Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2026)

Figure 50. United States Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 51. Canada Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 52. Mexico Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 53. Brazil Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 54. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region in 2026

Figure 55. APAC Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021-2026)

Figure 56. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026)

Figure 57. APAC Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2026)

Figure 58. China Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 59. Japan Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 60. South Korea Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 61. Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 62. India Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 63. Australia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 64. China Taiwan Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 65. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country in 2026

Figure 66. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021-2026)

Figure 67. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026)

Figure 68. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2026)

Figure 69. Germany Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 70. France Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 71. UK Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 72. Italy Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 73. Russia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 74. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2026)

Figure 75. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026)

Figure 76. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2026)

Figure 77. Egypt Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 78. South Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 79. Israel Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 80. Turkey Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 81. GCC Countries Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth 2021-2026 (\$ millions)

Figure 82. Manufacturing Cost Structure Analysis of Small Molecule Multi-target Angiogenesis Inhibitor in 2026

Figure 83. Manufacturing Process Analysis of Small Molecule Multi-target Angiogenesis Inhibitor

Figure 84. Industry Chain Structure of Small Molecule Multi-target Angiogenesis

Inhibitor

Figure 85. Channels of Distribution

Figure 86. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Forecast by Region (2027-2032)

Figure 87. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share Forecast by Region (2027-2032)

Figure 88. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share Forecast by Type (2027-2032)

Figure 89. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share Forecast by Type (2027-2032)

Figure 90. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share Forecast by Application (2027-2032)

Figure 91. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Small Molecule Multi-target Angiogenesis Inhibitor Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G59FAA353A5AEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G59FAA353A5AEN.html>